



## **Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference**

January 6, 2022

BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- [Talaris Therapeutics, Inc.](#) (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET.

A live webcast of the presentation will be available on the investors section of the Talaris website at [www.talaristx.com](http://www.talaristx.com). After the live webcast, the event will remain archived on the Talaris website for 30 days.

### **About Talaris Therapeutics**

Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.

### **Media Contact**

Marin Bergman  
Ten Bridge Communications  
[marin@tenbridgecommunications.com](mailto:marin@tenbridgecommunications.com)  
(818) 516-2746

### **Investor Contact**

Chris Brinzey  
ICR Westwicke  
[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)  
(339) 970-2843